orphan drugs

基本解釋

EU-wide harmonisation in the context of accessibility processes and price policies will reduce delays in the availability of orphan drugs.
全歐盟范圍內(nèi)統(tǒng)一的無(wú)障礙進(jìn)程和價(jià)格政策將減少延誤可用性孤兒藥。
The European orphan diseases market grapples with numerous challenges. Of these, the most serious are the lack of awareness, poor diagnosis and limited accessibility of orphan drugs.
歐洲孤兒疾病市場(chǎng)存在許多問(wèn)題。其中，最嚴(yán)重的是缺乏認(rèn)識(shí)，不良的診斷和有限利用孤兒藥物。
EU healthcare ministers should encourage frequent discussions with patients, patient support groups and industry representatives to ensure a transparent and rapid approval process for orphan drugs.
歐盟衛(wèi)生部長(zhǎng)會(huì)議鼓勵(lì)要經(jīng)常性的與患者，患者支持團(tuán)體和業(yè)界代表進(jìn)行溝通，以確保透明和快速審批程序孤兒藥物。

But before 1983, there were just 38 orphan drugs approved for use in the United States.
FORBES: The Lifesaving Promise Of The Pharmaceutical Drug Pipeline
Insurers may want to avoid negative publicity and will pay for orphan drugs, assuming patient populations remain small.
FORBES: Connect
New orphan drugs are just one of the reasons that individuals with hard-to-treat diseases have reason to hope.
FORBES: The Lifesaving Promise Of The Pharmaceutical Drug Pipeline

罕用藥
It is very necessary for the government to intervene to improve the accessibility of orphan drugs.2.
因此,在市場(chǎng)經(jīng)濟(jì)條件下,要促進(jìn)患者罕用藥的可及性,政府干預(yù)必不可少。